Dysautonomia International

Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine

Purpose

This study aims to develop and pilot test a patient decision aid (PtDA) for emergency department (ED)-initiated buprenorphine treatment for opioid use disorder (OUD). The PtDA will be evaluated for acceptability, impact on patient knowledge, decisional conflict, and buprenorphine uptake compared to treatment as usual (TAU).

Condition

Opioid Use Disorder

Eligibility

Eligible Ages: Over 18 Years
Eligible Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Age ≥18 - DSM-5 criteria for moderate-to-severe OUD - Speaks and reads English - Not currently prescribed MOUD - Post-ED discharge patients with access to video/email

Exclusion Criteria

Prisoners

Study Design

Phase: N/A
Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Health Services Research
Masking: None (Open Label)

Arm Groups

Arm	Description	Assigned Intervention
Experimental Patient Decision Aid	This arm will receive the patient decision aid	Behavioral: Patient Decision Aid for Opioid Use Disorder This will include information structured for patients about buprenorphine as a treatment options in the emergency department.
No Intervention Treatment as Usual	This will be treatment as usual without the patient decision aid

Recruiting Locations

Medical University of South Carolina
Charleston, South Carolina 29425

Contact:
Lindsey Jennings, MD
843-792-2300
jennil@musc.edu

More Details

Status: Recruiting
Sponsor: Medical University of South Carolina

Study Contact

Lindsey Jennings, MD, MPH
(843) 876-8023
jennil@musc.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.